Skip to Main Content

YCC Entrepreneurs

Over the past 20 years, Yale inventions have led to the creation of nearly 60 companies in the New Haven region that have attracted more than $1 billion of professional venture capital investment and have created over 1,400 jobs in the region. Many of these local companies are focused on oncology drug development based on science from Yale Cancer Center members, including:
arvinas logo
Research Program: Developmental Therapeutics

Arvinas is a pharmaceutical company focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases.

cybrexa logo
Research Program: Radiobiology & Radiotherapy
Research Program: Radiobiology & Radiotherapy

Cybrexa Therapeutics is an oncology-focused biotechnology company developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment.
Immunova logo
Research Program: Developmental Therapeutics

Immunova Pharmaceuticals has a proprietary Nanolipogel™ platform to deliver desired combinations of drugs in nanoparticle formulations to the disease microenvironment.

isoplexis logo
Research Program: Cancer Signaling Networks

IsoPlexis is transforming precision oncology in cell and cancer immunotherapy by defining the complete function of each cell for the first time.

kleo logo
Research Program: Developmental Therapeutics

Kleo Pharmaceuticals is pioneering a new class of immunotherapies utilizing small molecules to activate an individual’s own immune system to fight against cancers and infectious diseases.

kolltan
Research Program: Cancer Signaling Networks

Celldex Therapeutics acquired Kolltan Pharmaceuticals. Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate.

Research Program: Cancer Signaling Networks

Metamark is leading a shift in urological cancer care to enable patients and their physicians to make more informed treatment decisions that lead to better quality of life and lower cost of care.


MT logo
Research Program: Developmental Therapeutics

Modulate Therapeutics is a special purpose company created to develop one compound, IMM-01, to proof-of-concept.

historx logo
Research Program: Cancer Signaling Networks

Navigate (formally HistoRx) is developing novel diagnostic solutions to help turn innovative cancer treatment ideas into reality.


NextCure logo
Research Program: Cancer Immunology

NextCure is focused on discovering and developing next generation immunotherapy-based biologics for cancer and other immune-related disorders.

Onyx logo
Research Program: Developmental Therapeutics

Proteolix/Acquired by Onyx Pharma and develops and markets medicines for the treatment of cancer.
osmol logo
Research Program: Developmental Therapeutics

Osmol Therapeutics is developing a therapy for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) and Neurologic Impairment.

patrys logo
Research Program: Radiobiology & Radiotherapy
Research Program: Radiobiology & Radiotherapy

Nucleus Therapeutics/Acquired by Patrys is focused on the development of antibody therapies for major market opportunities in the oncology area.

phlipinc logo
Research Program: Developmental Therapeutics

pHILiP Inc. is focused on detecting, targeting, and treating acidic diseased tissue using selective insertion and folding of membrane peptides, primarily in oncology.

phytoceutica logo
Research Program: Developmental Therapeutics

PhytoCeutica develops herbal therapeutics for cancer and was acquired by Kadmon Pharmaceuticals.
logo for simcha.
Research Program: Cancer Immunology

Simcha Therapeutics in New Haven is developing potential therapies based on experiments from the Yale lab of Dr. Aaron Ring.
Vyriad logo
Research Program: Cancer Microbiology

Omnis Pharmaceuticals- merged to form Vyriad and is a clinical stage biotechnology company dedicated to delivering groundbreaking virus-based therapies for cancer patients.

vedanta logo
Research Program: Cancer Immunology

Vedanta Biosciences is using its proprietary platform to discover and develop a novel class of drugs that modulate pathways of interaction between the human microbiome and the host immune system to treat disease.

Yiviva logo
Research Program: Developmental Therapeutics

Yiviva is a biotechnology company to develop evidence-based botanical products to address aging-associated diseases.